Conference Coverage (ICAAC)

Lack of Early PK Data Can Invalidate AIDS Clinical Trials

Published in TB and Outbreaks Week, November 6th, 1995

AIDS clinical trials will fail if they do not take into account the dynamic interactions between experimental drugs, HIV, and virus-infected cells in individual patients, a pharmacologist warned.

Confusion about how best to use currently approved anti-HIV drugs is a direct result of a focus on the dosage, rather than the dynamics, of experimental drugs, early in the clinical trial process, according to Michael N. Dudley of Roger Williams Medical Center, Providence, Rhode Island.

Dudley spoke during a symposium held at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 17-20 in San Francisco,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1995-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry